Newsroom
Truveta news releases
FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds
BELLEVUE, Wash.—February 10, 2026—A new peer-reviewed study led by Truveta Research and collaborators finds that the US Food and Drug Administration’s (FDA) March 2024 expansion of semaglutide’s cardiovascular indication was followed by a rapid but short-lived...
Truveta deepens regulatory science leadership with appointment of John D. Seeger, PharmD, DrPH, FISPE as Senior Vice President of Evidence Services
Globally recognized pharmacoepidemiologist brings decades of experience advancing real-world evidence for regulatory decision-making. BELLEVUE, Wash.—February 9, 2026—Truveta today announced the appointment of John D. Seeger, PharmD, DrPH, FISPE, a global leader in...
Truveta Research study published in Contraception advances understanding of women’s health and clinical guideline adoption
BELLEVUE, Wash.—February 2, 2026—Truveta today announced the publication of a new Truveta Research study in Contraception, a leading peer-reviewed journal in reproductive health. The study leverages real-world data to examine trends in pain management during...
Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation
Bellevue, WA — January 27, 2026 — Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and execute clinical studies using the most complete, daily refreshed real-world data in the United States. Built...
Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer
Veteran physician–scientist brings decades of experience advancing oncology and genomics research across industry and academia. BELLEVUE, Wash. — January 26, 2026 — Truveta today announced the appointment of Johnathan M. Lancaster, MD, PhD as President and Chief...
Truveta launches Truveta Live Link
A breakthrough prospective research model that unites proprietary data, real-world clinical evidence, expert determination, and integrated storage in one solution BELLEVUE, Wash.—January 13, 2026—Truveta, the health system-led data and analytics company, today...
New Truveta research published in JAMA Network Open reveals declining timeliness in childhood MMR vaccination and identifies early predictors of missed immunizations
BELLEVUE, Wash.—January 2, 2026—Truveta today announced the publication of new peer-reviewed research in JAMA Network Open that provides one of the most comprehensive and timely analyses to date on childhood measles, mumps, and rubella (MMR) vaccination trends in the...
Truveta research published in JAMA Network Open shows rapid uptake of early measles vaccination during Texas outbreak
Truveta’s analysis of early measles, mumps, and rubella (MMR) vaccinations among Texas infants published today in JAMA Network Open. The study reveals a sharp increase in early MMR vaccinations among infants in Texas during the state’s 2025 measles outbreak, aligning...
Truveta research published in Radiology Advances introduces new AI model to estimate body composition from chest radiographs
Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest Radiographs and Clinical Data.” This groundbreaking study demonstrates the...
